Claudia Cardone

List of Publications by Year
in descending order

70 papers	1,691 citations	331670 21 h-index	302126 39 g-index
73 all docs	73 docs citations	73 times ranked	3494 citing authors

#	Article	IF	Citations
1	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. Cancer Treatment Reviews, 2019, 76, 22-32.	7.7	224
2	Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective. ESMO Open, 2020, 5, e000759.	4.5	161
3	Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Annals of Oncology, 2020, 31, 30-40.	1.2	124
4	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. Journal of Translational Medicine, 2020, 18, 405.	4.4	98
5	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World Journal of Gastroenterology, 2016, 22, 6345.	3.3	94
6	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World Journal of Gastroenterology, 2017, 23, 4675.	3.3	91
7	RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Annals of Oncology, 2018, 29, 112-118.	1.2	86
8	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With *RAS* Wild-type Metastatic Colorectal Cancer. JAMA Oncology, 2021, 7, 1529.	7.1	80
9	Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Annals of Oncology, 2016, 27, 1055-1061.	1.2	73
10	EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. Gastroenterology, 2017, 153, 178-190.e10.	1.3	72
11	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. Molecular Cancer Therapeutics, 2019, 18, 845-855.	4.1	58
12	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. Journal of Experimental and Clinical Cancer Research, 2019, 38, 41.	8.6	57
13	AXL is an oncotarget in human colorectal cancer. Oncotarget, 2015, 6, 23281-23296.	1.8	55
14	Impact of circulating tumor DNA mutant allele fraction on prognosis in *RAS*-mutant metastatic colorectal cancer. Molecular Oncology, 2019, 13, 1827-1835.	4.6	40
15	Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. Cancers, 2019, 11, 1504.	3.7	36
16	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. Cancer Treatment Reviews, 2020, 86, 102023.	7.7	34
17	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open, 2018, 3, e000299.	4.5	29
18	Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. Journal of Thoracic Oncology, 2018, 13, 810-820.	1.1	29

#	Article	IF	Citations
19	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. ESMO Open, 2017, 2, e000177.	4.5	27
20	Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. Cancers, 2019, 11, 859.	3.7	27
21	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. Oncotarget, 2017, 8, 68305-68316.	1.8	27
22	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. European Journal of Cancer, 2020, 138, 1-10.	2.8	23
23	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. Clinical Cancer Research, 2015, 21, 4153-4164.	7.0	21
24	Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. ESMO Open, 2017, 2, e000229.	4.5	14
25	Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 15.	8.6	13
26	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). ESMO Open, 2016, 1, e000107.	4.5	11
27	Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis. Future Oncology, 2018, 14, 2905-2913.	2.4	10
28	Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. ESMO Open, 2016, 1, e000086.	4.5	9
29	Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. Oncotarget, 2017, 8, 82773-82783.	1.8	8
30	Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. Medical Oncology, 2021, 38, 24.	2.5	7
31	Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.. Journal of Clinical Oncology, 2019, 37, TPS731-TPS731.	1.6	7
32	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. ESMO Open, 2019, 4, e000519.	4.5	5
33	The Use of Not-Negative Conclusions to Describe Results of Formally Negative Trials Presented at Oncology Meetings. JAMA Oncology, 2020, 6, 926.	7.1	5
34	Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. European Journal of Cancer, 2021, 150, 203-210.	2.8	5
35	AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). Annals of Oncology, 2018, 29, viii30.	1.2	2
36	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. Journal of Clinical Oncology, 2015, 33, TPS3634-TPS3634.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. Journal of Clinical Oncology, 2015, 33, TPS789-TPS789.	1.6	2
38	Abstract 2627: Inhibition of TGFβ in colorectal cancer cells is associated with a compensatory activation of AXL and p38 MAPK signaling pathways. Cancer Research, 2019, 79, 2627-2627.	0.9	2
39	Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?. Current Colorectal Cancer Reports, 2015, 11, 217-224.	0.5	1
40	blockade overcomes primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). Annals of Oncology, 2016, 27, vi1.	1.2	1
41	SYM004, a novel generation anti-EGFR inhibitor, is able to overcome acquired resistance to cetuximab such as MET activation, ERBB2 amplification and EGFR mutations, in colorectal cancer models. Annals of Oncology, 2016, 27, vi3.	1.2	1
42	Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four consensus molecular subtypes. Annals of Oncology, 2018, 29, viii5.	1.2	1
43	Receptor tyrosine kinase dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated colorectal cancer cell lines. Annals of Oncology, 2018, 29, viii1.	1.2	1
44	Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience. Annals of Oncology, 2019, 30, iv90.	1.2	1
45	Abstract 2619: Genetic landscape of KRAS-NRAS-BRAF-PIK3CA wild type metastatic colorectal cancer patients enrolled in the CAPRI clinical trial. , 2018, , .		1
46	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial). Annals of Oncology, 2015, 26, vi51.	1.2	0
47	Outcomes of elderly chemorefractory metastatic colorectal (mCRC) patients (pts) treated with regorafenib: a single institution experience. Annals of Oncology, 2016, 27, iv49.	1.2	0
48	Prevention of regorafenib related skin toxicity in refractory metastatic colorectal cancer (mCRC) patients (pts): a single institution experience. Annals of Oncology, 2016, 27, iv52.	1.2	0
49	Evaluation of burnout syndrome and personalized intervention in the medical oncology unit of second university of naples (sun). Annals of Oncology, 2016, 27, iv94.	1.2	0
50	AXL activation can promote resistance to MEK inhibition in a model of colorectal cancer (CRC). Annals of Oncology, 2016, 27, vi8.	1.2	0
51	Outcomes of long responders chemorefractory metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib: a single institution experience. Annals of Oncology, 2016, 27, iv50.	1.2	0
52	HER2 activation and epithelial-mesenchymal transition (EMT) are involved in the acquired resistance to cetuximab in combination with either regorafenib or refametinib. Annals of Oncology, 2016, 27, vi4.	1.2	0
53	Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by next generation sequencing (NGS) in the CAPRI- GOIM trial. Annals of Oncology, 2016, 27, vi181.	1.2	0
54	Evaluation of burnout syndrome and personalized intervention in the medical oncology unit of the Second University of Naples (SUN). Annals of Oncology, 2016, 27, vi472.	1.2	0

#	Article	IF	Citations
55	Transforming growth factor beta receptor (TGF&bgr;R) pathway is involved in ligand independent transactivation of AXL receptor in colorectal cancer (CRC) cell lines. Annals of Oncology, 2016, 27, vi8.	1.2	0
56	Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial. Annals of Oncology, 2017, 28, vi7-vi8.	1.2	0
57	The acquired resistance to the combination of the anti-EGFR cetuximab and the MEK-inhibitor refametinib in KRAS mutated colorectal cancer cell lines depends on PI3K-signalling. Annals of Oncology, 2017, 28, v2.	1.2	0
58	The acquired resistance to the combination of the anti-EGFR cetuximab and the MEK-inhibitor refametinib in KRAS mutated colorectal cancer cell lines depends on PI3K-signalling. Annals of Oncology, 2017, 28, vi14.	1.2	0
59	Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial. Annals of Oncology, 2017, 28, vi5.	1.2	0
60	EPHA2 receptor is involved in in vivo acquired resistance to anti-epidermal growth factor receptor (EGFR) treatment in metastatic colorectal cancer. Annals of Oncology, 2017, 28, vi13.	1.2	0
61	EPHA2 receptor is involved in in vivo acquired resistance to anti-Epidermal Growth Factor Receptor (EGFR) treatment in metastatic colorectal cancer (mCRC). Annals of Oncology, 2017, 28, v575.	1.2	0
62	Macrophage migration inhibitory factor overexpression is a mechanism of acquired resistance to anti-EGFR inhibitor cetuximab in human colorectal cancer cell line. Annals of Oncology, 2018, 29, viii198-viii199.	1.2	0
63	Functional inhibition of TGF-Î² in colorectal cancer cells and its interaction with AXL receptor. Annals of Oncology, 2018, 29, viii7.	1.2	0
64	Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data. Annals of Oncology, 2019, 30, iv91.	1.2	0
65	Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS. Annals of Oncology, 2019, 30, iv116.	1.2	0
66	Colorectal Cancer: Locoregional Disease. UNIPA Springer Series, 2021, , 605-616.	0.1	0
67	Pimasertib hydrochloride. MEK1/2 inhibitor, Treatment of malignant melanoma. Drugs of the Future, 2016, 41, 405.	0.1	0
68	Abstract 295: Synergism between oxaliplatin or irinotecan with the PARP inhibitor niraparib in a preclinical model of KRAS/BRAF mutated colorectal cancer is associated with MSI status. , 2019, , .		0
69	Abstract 2627: Inhibition of TGFÎ² in colorectal cancer cells is associated with a compensatory activation of AXL and p38 MAPK signaling pathways. , 2019, , .		0
70	Abstract 295: Synergism between oxaliplatin or irinotecan with the PARP inhibitor niraparib in a preclinical model of KRAS/BRAF mutated colorectal cancer is associated with MSI status. , 2019, , .		0